AUDRA BRAUN: Open Payments
NPI 1942449608 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$550 in 24 payments from 12 companies in 2025. Trend: 2023 $120 · 2024 $553 · 2025 $550
Food & beverage: $550
| Company | Payments | Amount |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 8 | $188 |
| Merck Sharp & Dohme LLC | 3 | $79 |
| Daiichi Sankyo Inc. | 3 | $62 |
| Astellas Pharma US Inc | 2 | $50 |
| PFIZER INC. | 1 | $24 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| PharmaEssentia USA Corporation | 1 | $22 |
| Stemline Therapeutics Inc. | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Genentech USA, Inc. | 1 | $22 |
Products named: TAVALISSE, KEYTRUDA, Padcev, BOSULIF, KISQALI, Enhertu, BESREMI, Orserdu.
Industry payments across CO — which companies pay providers there.
